Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001)
- PMID: 12110487
- DOI: 10.1016/s0959-8049(02)00122-3
Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001)
Abstract
This article summarises the progress that has been made in the adjuvant treatment of colorectal cancer over the last decade. In view of the consequent improvements in recurrence rates and in overall survival, the development of effective adjuvant treatments for colorectal cancer is considered as one of the most important to be made in clinical oncology over the last decade. Treatment recommendations based on evidence-based data and on expert opinions are summarised in this manuscript. However, a consensus cannot be reached on all aspects of treatment because of data that is currently emerging that will influence clinical practice and because of the many ongoing clinical trials. Those involved in the treatment of colorectal cancer should therefore be encouraged to continue to provide optimal patient care and to participate in well designed clinical trials in order to increase the evidence upon which they can base their clinical judgements and in order to make further progress.
Comment in
-
5'fluorouracil (FU) and folinic acid (FA) in either the weekly 'Roswell Park' or the 4-weekly 'Mayo' regimen should be standard chemotherapy for colon cancer.Eur J Cancer. 2003 Sep;39(14):2110. doi: 10.1016/s0959-8049(03)00327-7. Eur J Cancer. 2003. PMID: 12957468 No abstract available.
Similar articles
-
Colorectal cancer.Lancet. 1999 Mar 20;353(9157):1012-3. doi: 10.1016/S0140-6736(05)70721-2. Lancet. 1999. PMID: 10459935 No abstract available.
-
Colorectal cancer.Lancet. 1999 Mar 20;353(9157):1013. doi: 10.1016/S0140-6736(05)70722-4. Lancet. 1999. PMID: 10459936 No abstract available.
-
Adjuvant therapy of colorectal cancer.Surg Oncol Clin N Am. 1997 Oct;6(4):699-722. Surg Oncol Clin N Am. 1997. PMID: 9309089 Review.
-
[Concomitant preoperative radiochemotherapy for rectal cancers].Ann Chir. 1996;50(4):302-10; discussion 311. Ann Chir. 1996. PMID: 8758519 Review. French.
-
Will we ever succeed in resolving the adjuvant treatment dilemma in rectal cancer?J Surg Oncol. 2003 Feb;82(2):79-83. doi: 10.1002/jso.10197. J Surg Oncol. 2003. PMID: 12561061 No abstract available.
Cited by
-
Preoperative short-term radiation therapy (25 Gy, 2.5 Gy twice daily) for primary resectable rectal cancer (phase II).Br J Cancer. 2005 Apr 11;92(7):1209-14. doi: 10.1038/sj.bjc.6602485. Br J Cancer. 2005. PMID: 15785745 Free PMC article. Clinical Trial.
-
Reg4-induced mitogenesis involves Akt-GSK3β-β-Catenin-TCF-4 signaling in human colorectal cancer.Mol Carcinog. 2014 Feb;53 Suppl 1(0 1):E169-80. doi: 10.1002/mc.22088. Epub 2013 Oct 22. Mol Carcinog. 2014. PMID: 24151146 Free PMC article.
-
The application of mathematical modelling to aspects of adjuvant chemotherapy scheduling.J Math Biol. 2004 Apr;48(4):375-422. doi: 10.1007/s00285-003-0246-2. Epub 2003 Oct 27. J Math Biol. 2004. PMID: 15052504
-
Effectiveness of Adjuvant Chemotherapy with 5-FU/Leucovorin and Prognosis in Stage II Colon Cancer.J Korean Soc Coloproctol. 2011 Dec;27(6):322-8. doi: 10.3393/jksc.2011.27.6.322. Epub 2011 Dec 31. J Korean Soc Coloproctol. 2011. PMID: 22259748 Free PMC article.
-
Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy.Yonsei Med J. 2009 Dec 31;50(6):796-802. doi: 10.3349/ymj.2009.50.6.796. Epub 2009 Dec 18. Yonsei Med J. 2009. PMID: 20046420 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources